Presentation
5 March 2021 Biophotonics-based immunotherapy and checkpoint-based immunotherapy for cancer
Mark F. Naylor, Kaili Liu, Ashley R. Hoover, Wei R. Chen
Author Affiliations +
Abstract
Checkpoint inhibitor-based immunotherapy (CPI) has ushered in a new era in cancer treatment. CPI has shown promising outcomes in clinical studies, particularly in treating melanoma, non-small cell lung cancer, and a number of other cancers. However, CPI, currently using antibodies to CTLA-4, PD-1, and PD-L1, also has limitations. In most cases CPI can only be effective in a small percentage of patients of a given cancer. The major obstacles include initial resistance, refraction after initial response, high cost, and potential autoimmune side effects (particularly with high dose of checkpoint inhibitors). Biophotonics-based immunotherapy (BPI) uses a combination of phototherapy and immunostimulant, often through a local intervention. BPI has shown a great potential in inducing systemic, tumor-specific immunity against the target tumor. It has been used to treat metastatic cancers with promising outcomes. We anticipate that BPI can synergize with CPI by providing the quality and
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Mark F. Naylor, Kaili Liu, Ashley R. Hoover, and Wei R. Chen "Biophotonics-based immunotherapy and checkpoint-based immunotherapy for cancer", Proc. SPIE 11643, Biophotonics and Immune Responses XVI, 1164303 (5 March 2021); https://doi.org/10.1117/12.2585180
Advertisement
Advertisement
KEYWORDS
Cancer

Lung cancer

Tumors

Melanoma

Oncology

Phototherapy

Refraction

Back to Top